COMPANY HIGHLIGHTS
OncoTEX Inc. acquired the exclusive license to TEX Core, a novel anticancer drug platform, from The University of Texas. OncoTEX Inc. has partnered with researchers from the University of Texas to use the TEX Core platform to develop innovative texaphyrin based conjugates including lead oncology drug candidate OxaliTEX, as well as other novel multi-modal drugs to treat different types of cancers.
The lead indication for the OxaliTEX development program is platinum resistant ovarian cancer – the number one cause of gynecological cancer deaths worldwide. The future applications include lung cancer, colorectal cancer, and glioblastoma multiforme (GBM).
Contact
OncoTEX Inc. Investor Relations
investor.relations@oncotexinc.local